Randomized, Multi-dose, Placebo-controlled Phase 2 Trial of Oral Isoquercetin to Reduce Thrombin Generation in Ovarian Cancer
Memorial Sloan Kettering Cancer Center
Summary
The purpose of this study is to test whether isoquercetin can reduce markers in the blood that may indicate the risk of blood clots in people with ovarian cancer. The effects of isoquercetin will be compared with those of a placebo.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Participants must have histological- or cytological-confirmed ovarian cancer (epithelial, serous, or clear cell) and be receiving first-line chemotherapy (day 1 of isoquercetin should align with day 1 of cycle 1 or 2 of chemotherapy) for neoadjuvant, adjuvant, or advanced settings. * Minimum age 18 years * Life expectancy of greater than 6 months. * ECOG performance status \<2 * Participants must have preserved organ and marrow function as defined below: * Platelet count \> 50,000/mcL * Prothrombin time (PT) and partial thromboplastin time (PTT) \< 1.5 x institution…
Interventions
- DrugIsoquercetin
Cohort B and Cohort C will take isoquercetin
- OtherPlacebo
Placebo
Locations (8)
- Beth Israel Deaconess Medical Center (Data Collection Only)Boston, Massachusetts
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities)Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities)Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All Protocol Activities)Montvale, New Jersey
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities )Commack, New York
- Memorial Sloan Kettering Westchester (All Protocol Activities)Harrison, New York